Oligonucleotides CMC and Analytical Development Summit
The 2nd Oligonucleotides CMC and Analytical Development Summit returns this August to Boston.
With the unprecedented growth of the oligonucleotides market, reaching $2b by 2027 and with over 250 in the clinical phase of drug development, we now seek to unlock the potential of oligonucleotides beyond rare disease to treat large patient populations for undruggable targets.
In the last 12 months alone, there have been a number of advances in the field with Switch Therapeutics advancing their first RNAi technology, Avidity turbocharging their antibody-oligo conjugate and Ansa Biotech successfully synthesising the world’s longest oligonucleotide! Despite this, drug developers still face challenges in manufacturability and lack of concrete regulatory protocols.
Across 3 days, senior leaders will leverage knowledge and share thought leadership focused on improving analytical characterization, effectively preparing CMC data for IND filing and scaling up with long-term manufacturing in mind.
Built with experts from AstraZeneca, Alexion Pharmaceuticals and Biogen, revolutionize your drug development protocols by keeping your finger on the pulse at this hotly anticipated summit. With the market sky-rocketing and pipelines developing, this is your chance to be at the cutting edge!
Time: 12:00 pm – 4:00 pm
Venue details: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States
Prices:
Full Access Pass (Early and Group Discounts Available): USD 3898.00,
Conference Only (Early and Group Discounts Available): USD 3199.00
Speakers: Bing Guan, Associate Director, Drug Substance Development and Manufacturing – Iveric Bio, Carlo Zambonelli, Senior Director, Analytical Research and Development – Beam Therapeutics, George Bou-Assaf, Associate Director – Biogen, Mahender Gurram, Director – Entrada Therapeutics, Mahir Sinan Ozdemir, Associate Director – Scientific Integrator – Johnson and Johnson, Michael Hellerstein, Vice President Product Development – Vaxxinity, Mike Webb, Chief Executive Officer and Founder – Mike Webb Pharma, Pawan Kumar, Principal Scientist, Platform Lead – Takeda, Peter Smith, Principal Scientist, New Modalities Oligonucleotides – AstraZeneca, Rajendra Pandey, Vice President Chemistry – Cargene Therapeutics, Rakesh Dixit, President and Chief Scientific Officer – Bionavigen, Rick Welch, Vice President CMC – Sirnaomics, Robert Gronke, Senior Principle Scientist – Biogen, Satya Kuchimanchi, Senior Vice President Tech Ops – CAMP4 Therapeutics, Sibo Jiang, Head of CMC – Sanegene Bio, Tim Turner, Senior Manager, Synthetic Process Development – Alexion Pharmaceuticals, Xuan Zhou, Senior Scientist – Biogen, Zoe Yin, Independent Consultant, CMC – Self-Employed